Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Prime Medicine, Inc. (NYSE:PRME - Get Free Report) has received an average rating of "Moderate Buy" from the seven research firms that are covering the firm, MarketBeat Ratings reports. Three...